

Financial Tear Sheet

Corporate Profile


Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid's drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. In August 2018, Ovid announced that STARS, an international, double-blind, placebo-controlled, randomized Phase 2 clinical trial in adults and adolescents with Angelman syndrome, met its primary endpoint of safety and tolerability.

Stock Performance

OVID (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	\$1.80
Change (%)	▼ 0.05 (2.70%)
Volume	444,612
52 Week High	\$11.45
52 Week Low	\$1.72
Market Cap	\$45,610,111
Rolling EPS	-1.65
PE Ratio	0
Shares Outstanding	24,654,114

Data as of February 21, 2019 12:37 p.m. ET



Recent Headlines

February 20, 2019
Ovid Therapeutics Announces Pricing of \$30
Million of Securities in Concurrent Public
Offerings of Common and Preferred Stock

February 19, 2019
Ovid Therapeutics Announces Proposed
Concurrent Public Offerings of Common Stock
and Preferred Stock

January 4, 2019 Ovid Therapeutics Outlines 2019 Clinical and Business Priorities

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date Form February 19, 2019 424B5 February 19, 2019 424B5 February 19, 2019 8-K February 14, 2019 SC 13G

Corporate Governance

Jeremy Levin, D.Phil.,	Chairman of the
MB BChir	Board of
	Directors

Data provided by Nasdaq. Minimum 15 minutes delayed.

© Ovid Therapeutics.. All rights reserved.